Abstract:Glucagon-like peptide-1 receptor (GLP-1R) is a prime drug target for type 2 diabetes and obesity. The ligand initiated GLP-1R interaction with G protein has been well studied, but not with β-arrestin 1/2. Therefore, bioluminescence resonance energy transfer (BRET), mutagenesis and an operational model were used to evaluate the roles of 85 extracellular surface residues on GLP-1R in β-arrestin 1/2 recruitment triggered by three representative GLP-1R agonists (GLP-1, exendin-4 and oxyntomodulin). Residues selectively regulated β-arrestin 1/2 recruitment for diverse ligands, and β-arrestin isoforms were identified. Mutation of residues K130-S136, L142 and Y145 on the transmembrane helix 1 (TM1)-extracellular domain (ECD) linker decreased β-arrestin 1 recruitment but increased β-arrestin 2 recruitment. Other extracellular loop (ECL) mutations, including P137A, Q211A, D222A and M303A selectively affected β-arrestin 1 recruitment while D215A, L217A, Q221A, S223A, Y289A, S301A, F381A and I382A involved more in β-arrestin 2 recruitment for the ligands. Oxyntomodulin engaged more broadly with GLP-1R extracellular surface to drive β-arrestin 1/2 recruitment than GLP-1 and exendin-4; I147, W214 and L218 involved in β-arrestin 1 recruitment, while L141, D215, L218, D293 and F381 in β-arrestin 2 recruitment for oxyntomodulin particularly. Additionally, the non-conserved residues on β-arrestin 1/2 C-domains contributed to interaction with GLP-1R. Further proteomics profiling of GLP-1R stably expressed cell line upon ligands with or without β-arrestin 1/2 overexpression demonstrated both commonly and biasedly regulated proteins and pathways associated with cognate ligands and β-arrestins. Our study offers valuable information about ligand induced β-arrestin recruitment mediated by GLP-1R and consequent intracellular signaling events.

Identifying Key Residues and Key Interactions for the Binding of LEAP2 to Receptor GHSR1a.

Identifying the binding mechanism of LEAP2 to receptor GHSR1a.

LEAP2 Impairs the Capability of the Growth Hormone Secretagogue Receptor to Regulate the Dopamine 2 Receptor Signaling

Unusual Orthologs Shed New Light on the Binding Mechanism of Ghrelin to Its Receptor GHSR1a

LEAP2 is a more conserved ligand than ghrelin for fish GHSRs

LEAP2 Has Antagonized the Ghrelin Receptor GHSR1a Since Its Emergence in Ancient Fish.

LEAP-2: An Emerging Endogenous Ghrelin Receptor Antagonist in the Pathophysiology of Obesity

Spatial Approximations Between Residues 6 and 12 in the Amino-Terminal Region of Glucagon-Like Peptide 1 and Its Receptor A Region Critical for Biological Activity

Molecular Insights into Ago-Allosteric Modulation of the Human Glucagon-Like Peptide-1 Receptor

Liver-expressed antimicrobial peptide 2 functions independently of growth hormone secretagogue receptor in calorie-restricted mice

G Protein-Coupled Estrogen Receptor (Gper) Agonist Dual Binding Mode Analyses Toward Understanding Of Its Activation Mechanism: A Comparative Homology Modeling Approach

The GHSR1a antagonist LEAP2 regulates islet hormone release in a sex-specific manner

Exploring the molecular structures that confer ligand selectivity for galanin type II and III receptors

LEAP2 changes with body mass and food intake in humans and mice.

A unique hormonal recognition feature of the human glucagon-like peptide-2 receptor

Characterization and Functional Analysis of Three Novel Liver-Expressed Antimicrobial Peptide 2 (LEAP-2) in Glyptothorax Zanaensis

Selective Polypeptide Ligand Binding to the Extracellular Surface of the Transmembrane Domains of the Class B GPCRs GLP-1R and GCGR

Molecular basis of enhanced GLP-1 signaling mediated by GLP-1(9-36) in conjunction with LSN3318839

Liver-expressed antimicrobial peptide 2 is a hepatokine regulated by ghrelin, nutrients, and body weight

Distinct roles of the extracellular surface residues of glucagon-like peptide-1 receptor in β-arrestin 1/2 signaling

Involvement of POMC neurons in LEAP2 regulation of food intake and body weight